Invivyd Inc. (IVVD) is entering 2026 with strong momentum, driven by expanding revenues from its authorized COVID-19 antibody PEMGARDA (pemivibart), a robust cash position, and a pipeline of next-generation monoclonal antibodies targeting COVID-19, RSV, and measles.
With the pivotal DECLARATION Phase 3 trial of VYD2311 underway, Fast Track designation secured, and IND readiness for RSV candidate VBY329 expected later this year, Invivyd is positioning itself as a leader in antibody-based prophylaxis for infectious diseases.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com